Concepedia

Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study

Didier Maillet, Cathérine Belin, Christine Moroni, Stefania Cuzzubbo, Rénata Ursu, Lila Sirven-Villaros, Roberta Di Blasi, Catherine Thiéblemont

Neuro-Oncology · 2021 · 44 citations · 21 references

DOIFull text

Open access

Abstract

In this cohort of patients treated with CD19-targeted CAR T cells, we found no evidence for neurological or cognitive toxicity, 6-12 months after treatment.

References

21

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm, Douglas G. Altman, Matthias Egger et al. · The Lancet · 2007 · 17.1K citations · Full text

, , +9

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 3.9K citations · Full text

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster, Jakub Svoboda, Elise A. Chong et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Juliane Gust, Kevin A. Hay, Laïla‐Aïcha Hanafi et al. · Cancer Discovery · 2017 · 1.3K citations · Full text